Translate AMICOR contents if you like

Monday, March 19, 2007

Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update

Worldwide, cardiovascular disease (CVD) is the largest single cause of death among women, accounting for one third of all deaths.1 In many countries, including the United States, more women than men die every year of CVD, a fact largely unknown by physicians.2,3 The public health impact of CVD in women is not related solely to the mortality rate, given that advances in science and medicine allow many women to survive heart disease. For example, in the United States, 38.2 million women (34%) are living with CVD, and the population at risk is even larger.2 In China, a country with a population of approximately 1.3 billion, the age-standardized prevalence rates of dyslipidemia and hypertension in women 35 to 74 years of age are 53% and 25%, respectively, which underscores the enormity of CVD as a global health issue and the need for prevention of risk factors in the first place.4 As life expectancy continues to increase and economies become more industrialized, the burden of CVD on women and the global economy will continue to increase.5 The human toll and economic impact of CVD are difficult to overstate. In the United States alone, $403 billion was estimated to be spent in 2006 on health care or in lost productivity as a result of CVD, compared with $190 billion for cancer and $29 billion for human immunodeficiency virus (HIV).2 In addition to population-based and macroeconomic interventions, interventions in individual patients are key to reducing the incidence of CVD globally.6 Prevention of CVD is paramount to the health of every woman and every nation. Even modest control could have an enormous impact. It is projected that a reduction in the death rate due to chronic diseases by just 2% over 1 decade would prevent 36 million deaths.6

No comments: